- Home
- SUPN
as 12-18-2024 11:43am EST
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 2.0B | IPO Year: | 2012 |
| Target Price: | $36.00 | AVG Volume (30 days): | 285.1K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.07 | EPS Growth: | 130.79 |
| 52 Week Low/High: | $25.53 - $39.37 | Next Earning Date: | 11-04-2024 |
| Revenue: | $651,972,000 | Revenue Growth: | 6.79% |
| Revenue Growth (this year): | 7.82% | Revenue Growth (next year): | -3.32% |
Stock Insider Trading Activity of Supernus Pharmaceuticals Inc. (SUPN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | SUPN | Sr. VP of IP, CSO | Dec 3 '24 | Sell | $36.68 | 21,495 | $788,436.60 | 9,679 | |
| NEWHALL CHARLES W III | SUPN | Director | Nov 11 '24 | Sell | $36.24 | 10,700 | $387,768.00 | 130,275 | |
| Khattar Jack A. | SUPN | President, CEO | Nov 8 '24 | Sell | $36.29 | 125,000 | $4,536,250.00 | 926,172 | |
| Hudson Frederick M. | SUPN | Director | Nov 8 '24 | Sell | $36.28 | 8,722 | $316,434.16 | 28,395 | |
| GEMAYEL GEORGES | SUPN | Director | Nov 8 '24 | Sell | $36.30 | 10,787 | $391,568.10 | 13,315 | |
| Mottola Frank | SUPN | SVP, Quality, GMP, Ops, IT | Nov 7 '24 | Sell | $36.98 | 15,000 | $554,700.00 | 8,200 | |
| Khattar Jack A. | SUPN | President, CEO | Nov 7 '24 | Sell | $36.68 | 125,000 | $4,585,000.00 | 926,172 | |
| GEMAYEL GEORGES | SUPN | Director | Nov 7 '24 | Sell | $36.62 | 14,213 | $520,480.06 | 13,315 |
Latest Supernus Pharmaceuticals Inc. News
SUPN Breaking Stock News: Dive into SUPN Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada
Argus Research
8 days ago
SUPN: What does Argus have to say about SUPN?
Argus Research
15 days ago
SUPN: Raising target price to $39.00
Argus Research
22 days ago
SUPN: Raising target price to $38.00
GlobeNewswire
22 days ago
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
GlobeNewswire
a month ago
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
Argus Research
a month ago
SUPN: Raising target price to $40.00
MT Newswires
a month ago
Supernus Pharmaceuticals Insider Sold Shares Worth $4,536,250, According to a Recent SEC Filing
Compare SUPN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SUPN Supernus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.